English
中文
CAS:84371-65-3
Storage:Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity:HPLC≥98%
Appearance:Light yellow to yellow Solid
Manual Download
Examples of using this product（for reference only）
In Vitro:
Cell（HTR-8/SVneo cells，0 ~ 100 ng/mL Mifepristone, 6h）：
Mifepristone (Solarbio) was added in gradient concentrations (0, 25, 50 and 100 ng/ml) to HTR-8/SVneo cells which were pre-exposed to progesterone, and DAF levels were detected 6 h later.
Reference：
Zhang Y, Jin S. Mitigating placental injuries through up-regulating DAF in experimental APS mice: new mechanism of progesterone. Clin Exp Immunol. 2019 Sep;197(3):376-386. doi: 10.1111/cei.13313. Epub 2019 Jun 20. PMID: 31091357; PMCID: PMC6693963.
In Vivo:
Mice（APS model mouse, 2 mg/kg Mifepristone, from days 5·5 to 15·5.）:
To further confirm the protective effect of progesterone on APS model mouse, we carried out in-vivo progesterone antagonistic experiments. Progesterone (8 mg/kg) was given daily to mice from days 0·5 to 15·5 of pregnancy. Mifepristone (2 mg/kg) was added daily from days 5·5 to 15·5. Mice were euthanized on day 15·5 day of pregnancy. Fetal resorption rates, DAF, C3, interleukin (IL)-1β, IL-8 and tumour necrosis factor (TNF)-α levels were tested to detect the effects of mifepristone on model mice.
Reference：
Zhang Y, Jin S. Mitigating placental injuries through up-regulating DAF in experimental APS mice: new mechanism of progesterone. Clin Exp Immunol. 2019 Sep;197(3):376-386. doi: 10.1111/cei.13313. Epub 2019 Jun 20. PMID: 31091357; PMCID: PMC6693963.
